Boryung's Dukarb (Amlodipine Besylate+Fimasartan Potassium Trihydrate), which reexamination ends in May next year, is competitively developing. While multiple pharmaceutical companies such as DongKoo Bio have already begun developing generics, DongKook has also started developing IMD.

On the 22nd, the MFDS approved Dongkook's phase 1 clinical trial plan for DKF-407. The test drug names of DKF-407 are Fimasartan and S-Amlodipine, similar to Dukarb.

However, Amlodipine has started to differentiate itself by using S-Amlodipine, which maximizes the efficacy of the drug through isomer separation technology. Several pharmaceutical companies have joined the development competition since the con